Liposomes |
-
-
Biocompatible/biodegradable/non-immunogenic/non-toxic;
-
-
can incorporate hydrophilic and lipophilic drugs;
-
-
can incorporate various compounds, including enzymes and genetic material;
-
-
the formulation can be adjusted for a specific delivery route;
-
-
multifunctional/smart liposomes can be developed.
|
|
[55,56,57] |
Polymeric nanoparticles |
-
-
Numerous biomedical applications;
-
-
can entrap hydrophilic and lipophilic drugs;
-
-
biodegradable/biocompatible;
-
-
high encapsulation efficiency/drug loading.
|
-
-
Some polymers are rapidly degraded or possess a poor solubility in numerous solvents;
-
-
the scale-up process is challenging;
-
-
nanoparticles obtained from synthetic polymers might cause environmental concerns.
|
[55,58,59] |
Polymer–lipid hybrid nanoparticles |
-
-
The use of combined excipients can lead to biocompatible nanoparticles with low cytotoxic profile, improved stability and increased in vivo activity;
-
-
are able to deliver more than one active substance.
|
- |
[60] |
Micelles |
-
-
biocompatible;
-
-
possess prolonged blood circulation time/release profile;
-
-
the surface can be functionalized with ligands and peptides;
-
-
stimuli-sensitive nanoparticles can be obtained;
-
-
uniform in size.
|
|
[55,56,61] |
Polypeptide/protein-based nanoparticles |
-
-
Can incorporate hydrophilic and lipophilic drugs;
-
-
the surface can be modified with ligands;
-
-
can cross the blood–brain barrier;
-
-
the induced immune response is reduced in comparison with other types of nanoparticles;
-
-
easy manufacturing process and scale-up.
|
|
[62,63,64] |
Carbon Nanotubes |
|
|
[55,56,65] |
Metallic nanoparticles |
-
-
Can deliver more than one drug;
-
-
the surface properties can be easily modified during the preparation process;
-
-
non-immunogenic;
-
-
multiple biomedical applications.
|
|
[40,55,65] |